Akita-Based UMN Pharma To Invest ¥2 billion In New Vaccine Production Facility
This article was originally published in PharmAsia News
Japanese biopharmaceutical venture company UMN Pharma announced plans to invest ¥2 billion to build a new factory in Akita New Town Industrial Park. The construction starts this October and is estimated to be completed in October 2010. Akita prefecture will invest ¥9.5 million from its Akita Academy Venture Fund. UMN has been received local government funding since its start in 2004. (Click here for more - Japanese language
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.